This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
by Zacks Equity Research
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%.
VRTXPositive Net Change ADMAPositive Net Change CRSPPositive Net Change IMCRPositive Net Change
biotechs pharmaceuticals
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
by Zacks Equity Research
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechs
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
BAYRYPositive Net Change BEAMPositive Net Change ADMAPositive Net Change KRYSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
by Zacks Equity Research
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
VRTXPositive Net Change ADMAPositive Net Change CRSPPositive Net Change IMCRPositive Net Change
biotechs earnings
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
BAYRYPositive Net Change BEAMPositive Net Change ZTSNegative Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
by Zacks Equity Research
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
by Zacks Equity Research
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
JAZZPositive Net Change ADMAPositive Net Change AXSMPositive Net Change IMCRPositive Net Change
biotechs earnings
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
BAYRYPositive Net Change BEAMPositive Net Change ADMAPositive Net Change RXRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.
NVAXNegative Net Change ANIPPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
by Ahan Chakraborty
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
NVOPositive Net Change PCRXPositive Net Change RAREPositive Net Change ACADNegative Net Change DNLIPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.
SNYPositive Net Change NVAXNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
BioMarin's First-Quarter Earnings & Sales Beat Estimates
by Zacks Equity Research
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
SNYPositive Net Change BMRNPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs earnings medical pharmaceuticals
Viatris Q1 Earnings Release: What's in Store for the Stock?
by Zacks Equity Research
VTRS' Q1 results are likely to gain from new product launches in all major geographies.
VRTXPositive Net Change ANIPPositive Net Change DNLIPositive Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
TEVANegative Net Change BEAMPositive Net Change FOLDPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
by Zacks Equity Research
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
BAYRYPositive Net Change BEAMPositive Net Change ADMAPositive Net Change BPMCPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
by Zacks Equity Research
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
ALKSPositive Net Change BEAMPositive Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechs earnings
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
by Zacks Equity Research
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
REGNPositive Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
PFEPositive Net Change MRKPositive Net Change SMMTPositive Net Change
biotechs earnings medical pharmaceuticals
Implied Volatility Surging for Keros Therapeutics Stock Options
by Zacks Equity Research
Investors need to pay close attention to KROS stock based on the movements in the options market lately.
KROSPositive Net Change
biotechnology biotechs medical
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
BEAMPositive Net Change AGIOPositive Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechs earnings
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
by Ekta Bagri
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
GRFSPositive Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
by Zacks Equity Research
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
BIIBPositive Net Change RHHBYPositive Net Change SAGEPositive Net Change STOKPositive Net Change
biotechs earnings
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
by Zacks Equity Research
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
by Zacks Equity Research
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs earnings medical pharmaceuticals